JP2023515620A5 - - Google Patents

Info

Publication number
JP2023515620A5
JP2023515620A5 JP2022552208A JP2022552208A JP2023515620A5 JP 2023515620 A5 JP2023515620 A5 JP 2023515620A5 JP 2022552208 A JP2022552208 A JP 2022552208A JP 2022552208 A JP2022552208 A JP 2022552208A JP 2023515620 A5 JP2023515620 A5 JP 2023515620A5
Authority
JP
Japan
Prior art keywords
compound
formula
pharmaceutical composition
nucleic acid
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022552208A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023515620A (ja
JP7847852B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/020153 external-priority patent/WO2021174164A1/en
Publication of JP2023515620A publication Critical patent/JP2023515620A/ja
Publication of JP2023515620A5 publication Critical patent/JP2023515620A5/ja
Application granted granted Critical
Publication of JP7847852B2 publication Critical patent/JP7847852B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022552208A 2020-02-28 2021-02-28 スプライシングを調節するための化合物及び方法 Active JP7847852B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202062983541P 2020-02-28 2020-02-28
US62/983,541 2020-02-28
US202063007333P 2020-04-08 2020-04-08
US63/007,333 2020-04-08
US202063040484P 2020-06-17 2020-06-17
US63/040,484 2020-06-17
US202063072790P 2020-08-31 2020-08-31
US63/072,790 2020-08-31
US202063126492P 2020-12-16 2020-12-16
US63/126,492 2020-12-16
PCT/US2021/020153 WO2021174164A1 (en) 2020-02-28 2021-02-28 Compounds and methods for modulating splicing

Publications (3)

Publication Number Publication Date
JP2023515620A JP2023515620A (ja) 2023-04-13
JP2023515620A5 true JP2023515620A5 (https=) 2025-08-22
JP7847852B2 JP7847852B2 (ja) 2026-04-20

Family

ID=75143749

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022552209A Active JP7736700B2 (ja) 2020-02-28 2021-02-28 複素環アミド及びスプライシングを調節するためのその使用
JP2022552208A Active JP7847852B2 (ja) 2020-02-28 2021-02-28 スプライシングを調節するための化合物及び方法
JP2025142246A Pending JP2025172876A (ja) 2020-02-28 2025-08-28 複素環アミド及びスプライシングを調節するためのその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022552209A Active JP7736700B2 (ja) 2020-02-28 2021-02-28 複素環アミド及びスプライシングを調節するためのその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025142246A Pending JP2025172876A (ja) 2020-02-28 2025-08-28 複素環アミド及びスプライシングを調節するためのその使用

Country Status (15)

Country Link
US (3) US20240190879A1 (https=)
EP (3) EP4110785A1 (https=)
JP (3) JP7736700B2 (https=)
KR (2) KR20220158238A (https=)
CN (2) CN115515679A (https=)
AU (2) AU2021228284A1 (https=)
BR (2) BR112022017188A2 (https=)
CA (2) CA3169709A1 (https=)
CL (2) CL2022002342A1 (https=)
CO (2) CO2022013832A2 (https=)
CR (2) CR20220484A (https=)
IL (2) IL295957A (https=)
MX (2) MX2022010683A (https=)
SA (1) SA522440338B1 (https=)
WO (3) WO2021174165A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11407753B2 (en) 2017-06-05 2022-08-09 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
WO2019028440A1 (en) 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN114126613A (zh) 2019-02-05 2022-03-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
CN113661162A (zh) 2019-02-06 2021-11-16 斯基霍克疗法公司 用于调节剪接的方法和组合物
WO2020231977A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
BR112022023025A2 (pt) 2020-05-13 2023-03-28 Chdi Foundation Inc Moduladores de htt para tratar doença de huntington
US12065427B2 (en) 2021-04-29 2024-08-20 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating STING
WO2023034812A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
IL311132A (en) 2021-08-30 2024-04-01 Remix Therapeutics Inc Splicing Modulation Compounds and Methods
US12281116B2 (en) 2021-11-17 2025-04-22 Chdi Foundation, Inc. HTT modulators for treating Huntington's disease
JP2025522298A (ja) * 2022-06-15 2025-07-15 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための複素環式及びヘテロアリール化合物
WO2024086569A1 (en) 2022-10-17 2024-04-25 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
WO2024086570A1 (en) 2022-10-17 2024-04-25 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
TW202440080A (zh) * 2023-03-01 2024-10-16 美商雷密克斯醫療公司 用於調節剪接之化合物及方法
WO2024182788A1 (en) * 2023-03-01 2024-09-06 Remix Therapeutics Inc. Compounds and methods for modulating splicing
TW202535379A (zh) * 2024-01-26 2025-09-16 大陸商成都微芯藥業有限公司 Ｕｓｐ１抑制劑及其製備方法和用途
CN118166099B (zh) * 2024-02-05 2024-10-22 北京大学深圳医院 检测hsa_circ_0014088的试剂在制备诊断口腔鳞状细胞癌的试剂盒中的应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4809656B2 (ja) * 2005-09-29 2011-11-09 富士フイルム株式会社 ナフタロシアニン色素およびその製造方法
US20070254894A1 (en) * 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
EA201501088A1 (ru) * 2006-08-08 2017-01-30 Миллениум Фармасьютикалз, Инк. Гетероарильные соединения, применяемые в качестве ингибиторов e1 активирующих ферментов
WO2008040951A1 (en) * 2006-10-03 2008-04-10 Astrazeneca Ab Compounds
US20100029657A1 (en) * 2008-02-29 2010-02-04 Wyeth Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof
GB0807910D0 (en) * 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
ES2554513T3 (es) * 2008-05-23 2015-12-21 Novartis Ag Derivados de quinolinas y quinoxalinas como inhibidores de la proteína tirosina quinasa
US20110288089A1 (en) * 2009-01-22 2011-11-24 Syngenta Crop Protection Llc Insecticidal compounds
EP2435421A1 (en) * 2009-05-29 2012-04-04 Schering Corporation Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
CN102020643A (zh) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
TW201202230A (en) * 2010-05-24 2012-01-16 Mitsubishi Tanabe Pharma Corp Novel quinazoline compound
AU2011273931B2 (en) * 2010-06-28 2015-04-23 Merck Patent Gmbh 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer
JP2012028440A (ja) * 2010-07-21 2012-02-09 Hitachi Kokusai Electric Inc 基板処理装置及び半導体装置の製造方法
DK2812004T3 (en) 2012-02-10 2018-10-15 Ptc Therapeutics Inc COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY
MX336431B (es) * 2012-05-09 2016-01-18 Zoetis Services Llc Derivados de azetidina como agentes antiparasitarios.
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
EP2970312B1 (en) * 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
KR20140125061A (ko) * 2013-04-18 2014-10-28 (주)경인양행 유기발광 화합물 및 이를 포함하는 유기전계발광소자
WO2014209841A2 (en) * 2013-06-25 2014-12-31 F. Hoffmann-La Roche Ag Compounds for treating spinal muscular atrophy
BR112016026951B1 (pt) * 2014-06-25 2022-09-20 F. Hoffmann-La Roche Ag Imidazo[1,2-a]pirazin-1-il-benzamida, seu uso, e composições farmacêuticas
WO2016004254A1 (en) * 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
JP2017528498A (ja) * 2014-09-25 2017-09-28 アラクセス ファーマ エルエルシー Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター
CN104341403B (zh) * 2014-10-10 2016-06-22 山东盛华电子新材料有限公司 一种2,5-二杂环取代萘基噁烷衍生物及其制备方法
NL2013636B1 (en) * 2014-10-15 2016-10-04 Kraton Polymers Us Llc An accelerator system, a composition comprisng a synthetic isoprene polymer and the accelerator system, and dipped goods made from the composition.
WO2016128343A1 (en) 2015-02-09 2016-08-18 F. Hoffmann-La Roche Ag Compounds for the treatment of cancer
US10259816B2 (en) * 2015-04-24 2019-04-16 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
EP4249472A3 (en) 2015-05-30 2023-12-13 PTC Therapeutics, Inc. Methods for modulating rna splicing
IL294124B2 (en) 2015-12-10 2024-02-01 Ptc Therapeutics Inc Methods for treating huntington's disease
WO2017147328A1 (en) * 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
EA201991309A1 (ru) 2016-11-28 2019-11-29 Способы модуляции сплайсинга рнк
EP3573954A1 (en) * 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11407753B2 (en) * 2017-06-05 2022-08-09 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
KR20200017476A (ko) 2017-06-14 2020-02-18 피티씨 테라퓨틱스, 인크. Rna 스플라이싱의 변경 방법
WO2019028440A1 (en) * 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
KR20200057071A (ko) 2017-09-25 2020-05-25 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱 조절제의 스크리닝 및 확인을 위한 방법 및 조성물
EP3697786B1 (en) * 2017-10-18 2022-08-31 Blueprint Medicines Corporation Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
TW201942115A (zh) * 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
CN112272666A (zh) 2018-04-10 2021-01-26 斯基霍克疗法公司 用于治疗癌症的化合物
PL3814357T3 (pl) * 2018-06-27 2024-09-16 Ptc Therapeutics, Inc. Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona
BR112020026637A2 (pt) * 2018-06-27 2021-03-30 Reborna Biosciences, Inc. Agente profilático ou terapêutico para atrofia muscular espinhal
TWI834690B (zh) * 2018-07-18 2024-03-11 美商富曼西公司 用於防治無脊椎動物害蟲之異噁唑啉化合物
CN109180690A (zh) * 2018-10-15 2019-01-11 烟台显华化工科技有限公司 一类用作蓝色荧光材料的氮杂芳香化合物及其应用
WO2020123395A1 (en) * 2018-12-10 2020-06-18 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
WO2020132459A1 (en) * 2018-12-20 2020-06-25 The Regents Of The University Of Michigan Quinolinyl-pyrazine-carboxamide compounds and uses thereof
AU2020260629A1 (en) * 2019-04-22 2021-12-09 Betta Pharmaceuticals Co., Ltd Quinazoline compound and pharmaceutical application thereof
WO2021007378A1 (en) * 2019-07-11 2021-01-14 Ptc Therapeutics, Inc. Compounds for use in treating huntington's disease

Similar Documents

Publication Publication Date Title
JP2023515620A5 (https=)
JP2023515621A5 (https=)
JP2023515617A5 (https=)
JP2023515618A5 (https=)
JP2023520924A5 (https=)
JP2023520916A5 (https=)
JP2023520925A5 (https=)
JP6466348B2 (ja) スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用
JP2022505835A5 (https=)
IL295957A (en) Compounds and methods for modulating splicing
JP2024520481A5 (https=)
JP2020521741A5 (https=)
JP2006525359A5 (https=)
JP2013508373A5 (https=)
JP2019529490A5 (https=)
JP2017533968A5 (https=)
IL295955A (en) Compounds and methods for modulating splicing
RU2004126671A (ru) Гетероарилсоединения, полезные в качестве ингибиторов gsk-3
JP2014510774A5 (https=)
JP2008509166A5 (https=)
JP2011037841A5 (https=)
JP2013504593A5 (https=)
JP2020507589A5 (https=)
JP2020502047A5 (https=)
JP2013542261A5 (https=)